Myeloproliferative Neoplasms
Accelerated- and blast-phase MPNs: diagnosis, management, and current challenges
This episode of the VJHemOnc podcast focuses on accelerated and blast-phase myeloproliferative neoplasms (MPN-AP/BP), offering insights into their diagnosis and…
Date: 20th November 2025
iwMPN 2025 highlights: novel approaches to the upfront management of myelofibrosis, cardiovascular health in MPNs, & more
In this week’s VJHemOnc podcast, we’ll be sharing highlights in myeloproliferative neoplasms (MPNs) from the recent 3rd International Workshop on…
Date: 1st August 2025
Targeting mutant CALR in MPNs with antibodies & cellular therapy: the potential for disease modification
Today’s episode of the VJHemOnc podcast focuses on the targeting of mutant calreticulin (mutCALR) in myeloproliferative neoplasms (MPNs) – a…
Date: 14th July 2025
Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more!
VJHemOnc recently attended the 2025 ASCO Annual Meeting in Chicago, IL, where we gained insights into the latest advancements in…
Date: 30th June 2025
Highlights from EBMT 2025: preventing and managing GvHD, harnessing AI in transplant, & more
In this week’s VJHemOnc podcast, we’ll be sharing highlights from the 51st Annual Meeting of the EBMT, with a focus…
Date: 17th April 2025
Post-ASH MPN highlights: key trial updates in MF, novel approaches being explored in R/R disease, & more!
This podcast episode covers highlights in myeloproliferative neoplasms (MPNs) from the 66th American Society of Hematology (ASH) Annual Meeting and…
Date: 28th January 2025
Understanding BPDCN: dermatology and hematology perspectives on presentation, diagnosis, treatment, & multidisciplinary care
In this podcast, experts Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, Nicole LeBoeuf, MD, MPH, Dana-Farber Cancer Institute,…
Date: 28th November 2024
The treatment landscape and challenges in rare diseases: BPDCN, CMML, MPN-AP/BP, and VEXAS
This podcast features a discussion from the 6th International Workshop on Acute Leukemias (iwAL) 2024, which took place in Phoenix,…
Date: 6th November 2024
Insights into PV and ET: treating the AYA population, defining goals when treating patients, & more
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPNs) characterized by the overproduction of red blood cells and…
Date: 2nd September 2024
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in…
Date: 29th July 2024
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs
Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia…
Date: 3rd May 2024
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF
The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed…
Date: 22nd December 2023
